1.
Usmani SZ, Nahi H, Legiec W, Grosicki S, Vorobyev V, Spicka I, Hungria V, Korenkova S, Bahlis NJ, Flogegard M, Bladé J, Moreau P, Kaiser M, Iida S, Laubach J, Magen H, Cavo M, Hulin C, White D, De Stefano V, Lantz K, O’Rourke L, Heuck C, Delioukina M, Qin X, Nnane I, Qi M, Mateos M-V. Final analysis of the phase III non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma. haematol [Internet]. 2022Mar.31 [cited 2022Dec.6];107(10):2408-17. Available from: https://haematologica.org/article/view/haematol.2021.279459